CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560
Company Information
CymaBay Therapeutics (Nasdaq: CBAY)
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC) and NonAlcoholic SteatoHepatitis (NASH). We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.
Stock Information
| Last | Change | Volume |
Company Information
Investor Relations
Sujal Shah
(510) 293-8800
investors@cymabay.com
Recent News
Upcoming Event
Sep
24
2019
8:00 am ET
Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies
September 24, 2019 at 8:00 am ET